|
| ID | Sample size (T/C) | Mean age (years) | Diagnostic standards | Intervention | Comparison | Course duration (days) | Outcome | Adverse effects |
|
| Zhou and Liu [24] | 86 (46/40) | T: 46 ± 2
C: 48 ± 1.80 | Chinese diagnosis and treatment of CCCI guidelines (2004) | YXQN granules 4 g po tid + routine treatment | Flunarizine 5 mg po qn + routine treatment | 28 | Efficacy rate | None |
| Ding and Zhang [20] | 102 (54/48) | T: 47
C: 49 | Chinese diagnosis and treatment of CCCI guidelines (2004) | YXQN granules 4 g po tid + routine treatment | Flunarizine 5 mg po qn + routine treatment | 28 | Efficacy rate | None |
| He et al. [21] | 65 (34/31) | T: 63.30 ± 5.60
C: 63.70 ± 7.40 | Diagnostic criteria from the Japanese Ministry of Health (1990) | YXQN granules 4 g po tid + routine treatment | Nimodipine tablet 20 mg po tid + routine treatment | 30 | Efficacy rate, hemorheology (erythrocyte, fibrinogen, erythrocyte sedimentation rate) | None |
| Gu et al. [16] | 83 (42/41) | T: 67.20
C: 69.20 | Diagnostic criteria from the Japanese Ministry of Health (1990) | YXQN granules 4 g po tid + routine treatment | Nimodipine tablet 20 mg po tid + routine treatment | 56 | Efficacy rate, TCD (MCA, BA, PCA, VA) | None |
| Wang [32] | 87 (44/43) | T: 62 ± 7.50
C: 61.50 ± 8.50 | Diagnostic criteria from the Japanese Ministry of Health (2007) | YXQN granules 4 g po tid + routine treatment | Nimodipine tablet 20 mg po tid + routine treatment | 30 | Efficacy rate, TCD (ICA, BA, VA) | NR |
| Chang [25] | 52 (26/26) | T: 62.50 ± 4.60
C: 61.30 ± 4.20 | Diagnostic criteria from the 16th Stroke Society of Japan (2000) | YXQN granules 4 g po tid + routine treatment | Nimodipine tablet 20 mg po tid + routine treatment | 84 | Efficacy rate, MMSE, ADL | None |
| Li [31] | 80 (43/37) | T: 62 ± 6.30
C: 63 ± 5.80 | Chinese diagnosis and treatment of CCCI guidelines (unclear) | YXQN granules 4 g po tid + routine treatment | Nimodipine tablet 20 mg po tid + routine treatment | 30 | Efficacy rate, TCD (VA, BA was unclear) | NR |
| Shen [30] | 102 (52/50) | T: 58 ± 6.80
C: 57 ± 7.80 | Chinese diagnosis and treatment of CCCI guidelines (2007) | YXQN granules 4 g po tid + routine treatment | Nimodipine tablet 20 mg po tid + routine treatment | 30 | Efficacy rate, TCD (ICA, BA, VA) | |
| Wang [33] | 74 (37/37) | T: 54.30 ± 3.20
C: 54.20 ± 3.20 | Diagnostic criteria from the 16th Stroke Society of Japan (2000) | YXQN granules 4 g po tid + routine treatment | Routine treatment | 14 | Efficacy rate | NR |
| Zhu et al. [28] | 96 (48/48) | NR | Diagnostic criteria from the 16th Stroke Society of Japan (2000) | YXQN granules 4 g po tid + routine treatment | Routine treatment | 14 | Different efficacy rate, blood flow | T: 5
C: 0 |
| Li et al. [26] | 52 (26/26) | T: 84.60
C: 86.60 | Diagnostic criteria for CCCI (unclear) | YXQN granules 4 g po tid + routine treatment | Routine treatment | 90 | Efficacy rate | None |
| Liang [27] | 54 (27/27) | T: 66.40
C: 62.60 | Diagnostic criteria for CCCI (unclear) | YXQN granules 4 g po tid + routine treatment | Troxerutin tablet 0.2 g po tid + routine treatment | 90 | Efficacy rate | NR |
| Jia [29] | 90 (45/45) | NR | Diagnostic criteria from the 16th Stroke Society of Japan (2000) | YXQN granules 4 g po tid + routine treatment | Troxerutin tablet 0.2 g po tid + routine treatment | 90 | Efficacy rate, TCD (MCA, PCA, BA) | None |
| Zhang and Shi [22] | 104 (56/48) | T: 56 ± 7
C: 55 ± 5 | Diagnostic criteria for CCCI (unclear) | YXQN granules 4 g po tid + routine treatment | Troxerutin tablet 0.2 g po tid + routine treatment | 30 | Efficacy rate, TCD PI and RI (MCA, ACA, PCA), blood fluid | None |
| Bi and Chen [23] | 84 (42/42) | NR | Chinese diagnosis and treatment of CCCI guidelines (2002) | YXQN granules 4 mg po tid + routine treatment | Cinnarizine tablet 25 mg tid + routine treatment (specific drug was unclear) | 30 | Efficacy rate, TCD (MCA, VCA, ACA, VA, BA) | None |
|
